Adam Brufsky
Associate Director of Clinical Investigation for the University of Pittsburgh Cancer Institute · UPMC Medical Education
Credentials: · · · · ·
History
- Present
Cancer Therapeutics Program · UPMC Medical Education
- Present
- 1993–1995
Research
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
New England Journal of Medicine · 2018 · 1,827 citations
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2021 · 1,378 citations
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
New England Journal of Medicine · 2015 · 1,022 citations
49 papers
32 papers
- MR
31 papers
27 papers
- JO
25 papers
24 papers
24 papers
23 papers
Grants
- 2019–2032
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
National Cancer Institute · UG1
Contact PI · $7.7M · University of Pittsburgh at Pittsburgh
- 1997–2027
National Cancer Institute · P30
Project lead · $2.5M · University of Pittsburgh at Pittsburgh
- 2014–2019
NCI NCTN-Network Lead Academic Site at UPCI
National Cancer Institute · U10
Contact PI · $4.5M · University of Pittsburgh at Pittsburgh
- 1978–2003
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $120.4K · University of Pittsburgh at Pittsburgh
Clinical trials
- 2018–2022
Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer
Principal investigator · Completed · Phase 2
Daehwa Pharmaceutical Co., Ltd.
- 2024–2031
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Site PI · Recruiting · Phase 2
Vanderbilt-Ingram Cancer Center
- 2023–2033
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
- 2023–2030
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)